ARCHIVES

Benefit Seen In Novel Drug That Treats Gleevec Resistance

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

Roswell Park, Karmanos Read The Cancer Letter Interactive.

December 1, 2000

An Appreciation: Eddie Reed, 60, a Developer of Taxol

June 6, 2014

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

In Brief: Subcommittee Okays $980 Million for NCI In 1983, House Passes Waxman Bill, With Centers Line Item

October 8, 1982

In Brief: Online Genetics Glossary; ORI Misconduct Finding

February 5, 1999

New NCAB Chair Seeks Ideas, Opinions On Cancer Priorities

September 23, 1994